{"id":745056,"date":"2015-12-18T16:05:00","date_gmt":"2015-12-18T16:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/"},"modified":"2025-11-07T01:24:42","modified_gmt":"2025-11-07T06:24:42","slug":"fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/","title":{"rendered":"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve        Superior Overall Survival Compared to Ipilimumab     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved an expanded indication for KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab),<br \/>\n      the company\u2019s anti-PD-1 (programmed death receptor-1) therapy, to<br \/>\n      include the first-line treatment of patients with unresectable or<br \/>\n      metastatic melanoma. This approval marks the second FDA-approved<br \/>\n      indication in advanced melanoma for KEYTRUDA, which is now the first<br \/>\n      anti-PD-1 therapy approved for previously untreated advanced melanoma<br \/>\n      patients regardless of BRAF status. The FDA-approved dose of KEYTRUDA is<br \/>\n      2 mg\/kg every three weeks.\n    <\/p>\n<p>\n      In a Phase 3 trial, KEYNOTE-006, patients with unresectable or<br \/>\n      metastatic melanoma who were treated with KEYTRUDA experienced superior<br \/>\n      overall survival (OS) compared to those treated with ipilimumab. In this<br \/>\n      study supporting the first-line approval, patients given KEYTRUDA 10<br \/>\n      mg\/kg every two weeks demonstrated a 37 percent reduction in the risk of<br \/>\n      death and those given KEYTRUDA 10 mg\/kg every three weeks demonstrated a<br \/>\n      31 percent reduction in the risk of death, both compared to ipilimumab<br \/>\n      (hazard ratio: 0.63 [95% CI: 0.47, 0.83; p&lt;0.001] and hazard ratio: 0.69<br \/>\n      [95% CI: 0.52, 0.90; p=0.004], respectively).\n    <\/p>\n<p>\n      Immune-mediated adverse reactions occurred with KEYTRUDA including<br \/>\n      pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. Based<br \/>\n      on the severity of the adverse reaction, KEYTRUDA should be withheld or<br \/>\n      discontinued and corticosteroids administered. For more information<br \/>\n      regarding immune-mediated adverse reactions, see &#8220;Selected Important<br \/>\n      Safety Information&#8221; below.\n    <\/p>\n<p>\n      \u201cAs recently as five years ago, there were few treatment options for<br \/>\n      patients suffering from advanced melanoma,\u201d said Dr. Roger M.<br \/>\n      Perlmutter, president, Merck Research Laboratories. \u201cToday\u2019s news is<br \/>\n      another exciting milestone for KEYTRUDA and for patients with this<br \/>\n      disease. Data supporting the approval emerged from a large and diverse<br \/>\n      patient population, including patients with very advanced disease and<br \/>\n      patients whose tumors carried BRAF mutations, thus demonstrating both<br \/>\n      the breadth of our clinical development program for KEYTRUDA, and the<br \/>\n      potential of KEYTRUDA to extend the lives of those afflicted with this<br \/>\n      grievous malignancy.\u201d\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that works<br \/>\n      by increasing the ability of the body\u2019s immune system to help detect and<br \/>\n      fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its<br \/>\n      ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may<br \/>\n      affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      \u201cThis growing body of evidence in patients with advanced melanoma<br \/>\n      supports the expanded indication for KEYTRUDA,\u201d said Dr. Omid Hamid,<br \/>\n      Director of the Melanoma Center at The Angeles Clinic and Research<br \/>\n      Institute, and a principal investigator for the KEYTRUDA melanoma<br \/>\n      clinical program. \u201cThis approval highlights the importance of KEYTRUDA<br \/>\n      for advanced melanoma, where we are in need of additional treatment<br \/>\n      options.\u201d\n    <\/p>\n<p>\n      <b>Data Supporting First-Line Indication in Advanced Melanoma and<br \/>\n      KEYTRUDA Full Approval<\/b>\n    <\/p>\n<p>\n      The approval was based on data from a multicenter, controlled, Phase 3<br \/>\n      study, KEYNOTE-006, which evaluated KEYTRUDA compared to ipilimumab in<br \/>\n      834 patients with unresectable or metastatic melanoma with progression<br \/>\n      of disease; no prior therapy with ipilimumab; and prior therapy with at<br \/>\n      most one other systemic treatment. Patients were randomized (1:1:1) to<br \/>\n      receive KEYTRUDA at a dose of 10 mg\/kg every two (n=279) or three weeks<br \/>\n      (n=277) until disease progression or unacceptable toxicity, or<br \/>\n      ipilimumab, the standard of care at the time of the study, at a dose of<br \/>\n      3 mg\/kg every three weeks for four doses unless discontinued earlier for<br \/>\n      disease progression or unacceptable toxicity (n=278). The primary<br \/>\n      efficacy outcome measures were OS and progression-free survival (PFS)<br \/>\n      (as assessed by Blinded Independent Central Review (BICR) using Response<br \/>\n      Evaluation Criteria in Solid Tumors (RECIST) v1.1). Secondary efficacy<br \/>\n      outcome measures were overall response rate (ORR) and response duration.<br \/>\n      KEYTRUDA 10 mg\/kg every two or three weeks showed superior OS compared<br \/>\n      to ipilimumab (hazard ratio: 0.63 [95% CI: 0.47, 0.83; p&lt;0.001] and<br \/>\n      hazard ratio: 0.69 [95% CI: 0.52, 0.90; p=0.004], respectively). Median<br \/>\n      PFS was 5.5 months (95% CI: 3.4, 6.9), 4.1 months (95% CI: 2.9, 6.9),<br \/>\n      and 2.8 months (95% CI: 2.8, 2.9) with KEYTRUDA 10 mg\/kg every two<br \/>\n      weeks, KEYTRUDA 10 mg\/kg every three weeks and ipilimumab, respectively.<br \/>\n      For PFS, both schedules for KEYTRUDA 10 mg\/kg every two or three weeks<br \/>\n      resulted in superior outcomes compared to ipilimumab (hazard ratio: 0.58<br \/>\n      [95% CI: 0.46, 0.72; p&lt;0.001] and hazard ratio: 0.58 [95% CI: 0.47,<br \/>\n      0.72; p&lt;0.001], respectively). KEYTRUDA every two or three weeks<br \/>\n      demonstrated a 42 percent reduction in the risk of disease progression<br \/>\n      or death as compared to ipilimumab. The ORR was 34 percent (95% CI: 28,<br \/>\n      40) with KEYTRUDA 10 mg\/kg every two weeks and 33 percent (95% CI: 27,<br \/>\n      39) with KEYTRUDA (pembrolizumab) 10 mg\/kg every three weeks, as<br \/>\n      compared with 12 percent (95% CI: 8, 16) with ipilimumab. KEYTRUDA 10<br \/>\n      mg\/kg every two weeks and three weeks achieved partial response rates of<br \/>\n      29 percent and 27 percent, respectively, and complete response rates of<br \/>\n      5 percent and 6 percent, respectively; there was a 10 percent partial<br \/>\n      response rate and 1 percent complete response rate for ipilimumab. Among<br \/>\n      the 94 patients randomized to KEYTRUDA 10 mg\/kg every two weeks with an<br \/>\n      objective response, response durations ranged from 1.4+ to 8.2 months.<br \/>\n      Among the 91 patients randomized to KEYTRUDA 10 mg\/kg every three weeks<br \/>\n      with an objective response, response durations ranged from 1.4+ to 8.1+<br \/>\n      months.\n    <\/p>\n<p>\n      Eighty percent of patients had PD-L1 positive melanoma, 18 percent had<br \/>\n      PD-L1 negative melanoma, and 2 percent had unknown PD-L1 status<br \/>\n      (positive: greater than or equal to 1 percent of tumor cells using an<br \/>\n      Investigational Use Only assay). BRAF mutations were reported in 36<br \/>\n      percent of patients, of which 46 percent were previously treated with a<br \/>\n      BRAF-inhibitor. Patients with BRAF V600E mutated melanoma were not<br \/>\n      required to have received prior BRAF inhibitor therapy.\n    <\/p>\n<p>\n      The most commonly reported adverse reactions were fatigue (28% with<br \/>\n      KEYTRUDA&nbsp;vs. 28% with ipilimumab), diarrhea (26% with KEYTRUDA), rash<br \/>\n      (24% with KEYTRUDA vs. 23% with ipilimumab), and nausea (21% with<br \/>\n      KEYTRUDA).&nbsp;Corresponding incidence rates are listed for ipilimumab only<br \/>\n      for those adverse reactions that occurred at the same or lower rate than<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2,117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for four months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      <b>FDA Approves Labeling Update in Advanced Melanoma: Supporting Data<br \/>\n      from<\/b> <b>KEYNOTE-002<\/b>\n    <\/p>\n<p>\n      Additionally, the FDA approved an update to the product labeling for<br \/>\n      KEYTRUDA for the treatment of patients with ipilimumab-refractory<br \/>\n      advanced melanoma. This update is based on results from the randomized<br \/>\n      Phase 2 trial, KEYNOTE-002, which demonstrated KEYTRUDA was superior to<br \/>\n      investigator\u2019s choice chemotherapy.\n    <\/p>\n<p>\n      KEYNOTE-002 is a multicenter, randomized controlled study of KEYTRUDA<br \/>\n      (pembrolizumab) 2 mg\/kg every three weeks or 10 mg\/kg every three weeks<br \/>\n      compared to investigator\u2018s choice chemotherapy (dacarbazine,<br \/>\n      temozolomide, carboplatin plus paclitaxel, paclitaxel, or carboplatin)<br \/>\n      in 540 patients with unresectable or metastatic melanoma with<br \/>\n      progression of disease; refractory to two or more doses of ipilimumab<br \/>\n      and, if BRAF V600 mutation positive, a BRAF or MEK inhibitor; and<br \/>\n      disease progression within 24 weeks following the last dose of<br \/>\n      ipilimumab. Patients on chemotherapy who experienced progression of<br \/>\n      disease were offered KEYTRUDA. Median PFS was 2.9 months (95% CI: 2.8,<br \/>\n      3.8), 2.9 months (95% CI: 2.8, 4.7), and 2.7 months (95% CI: 2.5, 2.8)<br \/>\n      with KEYTRUDA 2 mg\/kg every three weeks (n=180), KEYTRUDA 10 mg\/kg every<br \/>\n      three weeks (n=181) and chemotherapy (n=179), respectively. Doses of<br \/>\n      KEYTRUDA 2 mg\/kg or 10 mg\/kg every three weeks were superior compared to<br \/>\n      chemotherapy for the PFS primary endpoint (hazard ratio: 0.57 [95% CI:<br \/>\n      0.45, 0.73; p&lt;0.001] and hazard ratio: 0.50 [95% CI: 0.39, 0.64;<br \/>\n      p&lt;0.001], respectively). KEYTRUDA 2 mg\/kg every three weeks demonstrated<br \/>\n      a 43 percent reduction in the risk of disease progression or death<br \/>\n      compared to chemotherapy. There was no statistically significant<br \/>\n      difference between KEYTRUDA and chemotherapy in the interim OS analysis.<br \/>\n      The ORR was 21 percent (95% CI: 15, 28) with KEYTRUDA 2 mg\/kg every<br \/>\n      three weeks and 25 percent (95% CI: 19, 32) with KEYTRUDA 10 mg\/kg every<br \/>\n      three weeks, as compared with 4 percent (95% CI: 2, 9) with<br \/>\n      chemotherapy. KEYTRUDA 2 mg\/kg and 10 mg\/kg every three weeks achieved<br \/>\n      partial response rates of 19 percent and 23 percent, respectively, and<br \/>\n      complete response rates of 2 percent and 3 percent, respectively; there<br \/>\n      was a 4 percent partial response rate and no complete responses for<br \/>\n      chemotherapy. Among the 38&nbsp;patients randomized to KEYTRUDA 2&nbsp;mg\/kg with<br \/>\n      an objective response, response durations ranged from 1.3+ to<br \/>\n      11.5+&nbsp;months. Among the 46&nbsp;patients randomized to KEYTRUDA 10&nbsp;mg\/kg with<br \/>\n      an objective response, response durations ranged from 1.1+ to<br \/>\n      11.1+&nbsp;months.\n    <\/p>\n<p>\n      The most commonly reported adverse reactions were fatigue (43% with<br \/>\n      KEYTRUDA), pruritus (28% with KEYTRUDA vs. 8% with chemotherapy), rash<br \/>\n      (24% with KEYTRUDA vs. 8% with chemotherapy), constipation (22% with<br \/>\n      KEYTRUDA vs.&nbsp;20% with chemotherapy), nausea (22% with KEYTRUDA),<br \/>\n      diarrhea (20% with KEYTRUDA vs. 20% with chemotherapy), and decreased<br \/>\n      appetite (20% with KEYTRUDA).&nbsp;Corresponding incidence rates are listed<br \/>\n      for chemotherapy only for those adverse reactions that occurred at the<br \/>\n      same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was initially approved in 2014 under the FDA\u2019s accelerated<br \/>\n      approval process for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma and disease progression following ipilimumab and, if<br \/>\n      BRAF V600 mutation positive, a BRAF inhibitor. At the time of the<br \/>\n      initial approval, an improvement in survival or disease-related symptoms<br \/>\n      was not established. In accordance with the accelerated approval<br \/>\n      process, full approval was contingent upon verification and description<br \/>\n      of clinical benefit, which has now been demonstrated in KEYNOTE-002 and<br \/>\n      KEYNOTE-006.\n    <\/p>\n<p class=\"bwalignl\">\n      <b>Selected Important Safety Information for KEYTRUDA (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA. Pneumonitis occurred in 32 (2%) of 1,567 patients<br \/>\n      with melanoma, including Grade 1 (0.8%), 2 (0.8%), and 3 (0.4%)<br \/>\n      pneumonitis. Pneumonitis occurred in 19 (3.5%) of 550 patients with<br \/>\n      non-small cell lung cancer (NSCLC), including Grade 2 (1.1%), 3 (1.3%),<br \/>\n      4 (0.4%), or 5 (0.2%) pneumonitis. Monitor patients for signs and<br \/>\n      symptoms of pneumonitis. Evaluate suspected pneumonitis with<br \/>\n      radiographic imaging. Administer corticosteroids for Grade 2 or greater<br \/>\n      pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue<br \/>\n      KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1,567 patients with<br \/>\n      melanoma, including Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis.<br \/>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in 16 (1%) of 1,567 patients with<br \/>\n      melanoma, including Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis.<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1,567 patients with melanoma,<br \/>\n      including Grade 2 (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis.<br \/>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients with NSCLC, which was<br \/>\n      Grade 3 in severity. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1,567 patients with melanoma,<br \/>\n      including Grade 2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism<br \/>\n      occurred in 127 (8.1%) of 1,567 patients with melanoma, including Grade<br \/>\n      3 (0.1%) hypothyroidism. Hyperthyroidism occurred in 10 (1.8%) of 550<br \/>\n      patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%)<br \/>\n      hyperthyroidism. Hypothyroidism occurred in 38 (6.9%) of 550 patients<br \/>\n      with NSCLC, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism. Thyroid<br \/>\n      disorders can occur at any time during treatment. Monitor patients for<br \/>\n      changes in thyroid function (at the start of treatment, periodically<br \/>\n      during treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA<br \/>\n      (pembrolizumab)<b> <\/b>for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2,117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in 7 (0.4%) of 1,567 patients with<br \/>\n      melanoma, including Grade 2 (0.2%), 3 (0.2%) and Grade 4 (0.1%)<br \/>\n      nephritis. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the immune-mediated adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients<br \/>\n      with melanoma: arthritis (1.6%), exfoliative dermatitis, bullous<br \/>\n      pemphigoid, uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. The<br \/>\n      following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients with NSCLC: rash, vasculitis,<br \/>\n      hemolytic anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2,117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      In Trial 6, KEYTRUDA was discontinued due to adverse reactions in 9% of<br \/>\n      555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions were fatigue (28% with<br \/>\n      KEYTRUDA vs. 28% with ipilimumab), diarrhea (26% with KEYTRUDA), rash<br \/>\n      (24% with KEYTRUDA vs. 23% with ipilimumab), and nausea (21% with<br \/>\n      KEYTRUDA). Corresponding incidence rates are listed for ipilimumab only<br \/>\n      for those adverse reactions that occurred at the same or lower rate than<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      In Trial 2, KEYTRUDA was discontinued due to adverse reactions in 12% of<br \/>\n      357 patients with advanced melanoma; the most common (\u22651%) were general<br \/>\n      physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculo-papular rash (1%).<br \/>\n      The most common adverse reactions were fatigue (43% with KEYTRUDA),<br \/>\n      pruritus (28% with KEYTRUDA vs. 8% with chemotherapy), rash (24% with<br \/>\n      KEYTRUDA vs. 8% with chemotherapy), constipation (22% with KEYTRUDA vs.<br \/>\n      20% with chemotherapy), nausea (22% with KEYTRUDA), diarrhea (20% with<br \/>\n      KEYTRUDA vs. 20% with chemotherapy), and decreased appetite (20% with<br \/>\n      KEYTRUDA). Corresponding incidence rates are listed for chemotherapy<br \/>\n      only for those adverse reactions that occurred at the same or lower rate<br \/>\n      than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients with NSCLC. Serious adverse reactions occurred in 38% of<br \/>\n      patients. The most frequent serious adverse reactions reported in 2% or<br \/>\n      more of patients were pleural effusion, pneumonia, dyspnea, pulmonary<br \/>\n      embolism, and pneumonitis. The most common adverse reactions (reported<br \/>\n      in at least 20% of patients) were fatigue (44%), decreased appetite<br \/>\n      (25%), cough (29%), and dyspnea (23%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to Patients<\/b>\n    <\/p>\n<p>\n      Merck provides multiple programs to help ensure patients who are<br \/>\n      prescribed KEYTRUDA have access to our anti-PD-1 therapy. The <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merckaccessprogram-keytruda.com%2F&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=Merck+Access+Program&amp;index=1&amp;md5=a9e27e969a2972a275dd00d93b241156\" rel=\"nofollow\">Merck<br \/>\n      Access Program<\/a> provides reimbursement support for eligible patients<br \/>\n      receiving KEYTRUDA, including help with out-of-pocket costs and co-pay<br \/>\n      assistance. Merck also offers financial assistance for eligible patients<br \/>\n      who are uninsured through our patient assistance program. More<br \/>\n      information is available by calling 1-855-257-3932 or visiting <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merckaccessprogram-keytruda.com&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=www.merckaccessprogram-keytruda.com&amp;index=2&amp;md5=d561a351f55f2c42ade376a5c9774b7f\" rel=\"nofollow\">www.merckaccessprogram-keytruda.com<\/a>.\n    <\/p>\n<p>\n      Merck also offers a 24\/7 Patient Support program called KEY+YOU. The<br \/>\n      KEY+YOU program is staffed by compassionate nurses offering patients<br \/>\n      phone calls, email check-ins, wellness support, and referrals to<br \/>\n      community\/peer groups as part of a comprehensive plan of support. A<br \/>\n      patient may enroll in the program by dialing 1-85-KEYTRUDA or visiting <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.Keytruda.com&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=www.Keytruda.com&amp;index=3&amp;md5=56eba821eaf35fcc3709bf0d99b212a6\" rel=\"nofollow\">www.Keytruda.com<\/a>.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae <\/b><\/sup><b>(pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. The NSCLC<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for this indication may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=4&amp;md5=be4b6679fea951c995073ab6601c656d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=5&amp;md5=c678611d4c70e1188f99ed84c102a6c3\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=Twitter&amp;index=6&amp;md5=9a7685c32955a57c9d68fb1a1624895c\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=Facebook&amp;index=7&amp;md5=3c9e31937344e2b0090c610e8f2baee9\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=6e25c481a29c6b04e89d4aea4b211508\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=6c48f468ccce3968f2071f8559c641f2\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC&#8217;s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=c93497097a2441737aa4a9ef199dc67a\" rel=\"nofollow\">www.sec.gov<\/a>)<sub>.<\/sub>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf+&amp;index=11&amp;md5=8e613e9eb6ca15a57c3319754ae180e5\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<br \/>\n      <\/b><\/a><b>and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51247317&amp;newsitemid=20151218005982&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=12&amp;md5=0db87f5fc55c6786a222e62af1026d49\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151218005982r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>An        Phan, 908-255-6325<br \/>or<br \/>Investor Contacts:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indication in advanced melanoma for KEYTRUDA, which is now the first anti-PD-1 therapy approved for previously untreated advanced melanoma patients regardless of BRAF status. The FDA-approved dose of KEYTRUDA is 2 mg\/kg every three weeks. In a Phase 3 trial, KEYNOTE-006, patients with unresectable or metastatic melanoma who were treated with KEYTRUDA experienced superior overall survival (OS) compared to those treated with ipilimumab. In this study supporting the first-line approval,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745056","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indication in advanced melanoma for KEYTRUDA, which is now the first anti-PD-1 therapy approved for previously untreated advanced melanoma patients regardless of BRAF status. The FDA-approved dose of KEYTRUDA is 2 mg\/kg every three weeks. In a Phase 3 trial, KEYNOTE-006, patients with unresectable or metastatic melanoma who were treated with KEYTRUDA experienced superior overall survival (OS) compared to those treated with ipilimumab. In this study supporting the first-line approval,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\\\/\",\"name\":\"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-12-18T16:05:00+00:00\",\"dateModified\":\"2025-11-07T06:24:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma - Merck.com","og_description":"KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indication in advanced melanoma for KEYTRUDA, which is now the first anti-PD-1 therapy approved for previously untreated advanced melanoma patients regardless of BRAF status. The FDA-approved dose of KEYTRUDA is 2 mg\/kg every three weeks. In a Phase 3 trial, KEYNOTE-006, patients with unresectable or metastatic melanoma who were treated with KEYTRUDA experienced superior overall survival (OS) compared to those treated with ipilimumab. In this study supporting the first-line approval,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:42+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/","name":"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-12-18T16:05:00+00:00","dateModified":"2025-11-07T06:24:42+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-for-the-treatment-of-patients-with-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Expanded Indication for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the Treatment of Patients with Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ec2dff7b-a319-4491-92ec-84fc0646217b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/FDA-Approves-Expanded-Indication-for-Mercks-KEYTRUDA-pembrolizumab-for-the-Treatment-of-Patients-with-Advanced-Melanoma-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745056\/revisions"}],"predecessor-version":[{"id":3674555,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745056\/revisions\/3674555"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745056"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}